This poster was originally presented at the SERAM 2012 meeting, May 24-28, in Granada/ES. Este póster ha sido presentado originalmente en el congreso de la SERAM 2012, 24-28 de mayo, en Granada/ES.
www.seram.es
Type:
Presentación Electrónica Educativa
Keywords:
Metabolic disorders, Congenital, Tissue characterisation, Imaging sequences, Diagnostic procedure, Physiological studies, MR-Functional imaging, MR-Diffusion/Perfusion, MR, Thorax, Cardiovascular system, Cardiac
Authors:
M. L. Sánchez Alegre, A. E. Madrid Vallenilla, J. De la Torre Fernández, J. Alarcón Rodríguez, R. Yotti Alvarez, M. Ruiz Lozano; Madrid/ES
DOI:
10.1594/seram2012/S-1501
Conclusiones
CONCLUSIONES:
Las miocardiopatías secundarias representan un reto diagnóstico,
dada la inespecificidad de los síntomas de debut y el solapamiento entre las diferentes entidades.
Si bien la ecocardiografía es una técnica adecuada para la aproximación inicial a las miocardiopatías,
la RM se ha convertido en una técnica de gran utilidad en la valoración de la función cardíaca y en el seguimiento de pacientes con cardiopatías secundarias a enfermedades sistémicas.
Las múltiples secuencias de RM y especialmente las de realce tardío permiten,
junto a un adecuado enfoque clínico,
estrechar el diagnóstico diferencial,
mejorar la estratificación del riesgo clínico y valorar la efectividad de los tratamientos.
BIBLIOGRAFIA:
- Richardson P,
McKenna W,
Bristow M,
y cols.
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies.
Circulation.
1996;93:84-2.
- Maron BJ,
Towbin JA,
Thiene G y cols.
American Heart Association; Council on Clinical Cardiology,
Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention.
Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology,
Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.
Circulation.
2006;113:1807-16.
- Elliott P,
Andersson B,
Arbustini E y cols.
Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur Heart J.
2008;29:270-6.
- Nihoyannopoulos P.
Amyloid heart disease.
Current Opin Cardiol.
1987;2:371–376
- Belloni E,
De Cobelli E,
Esposito A.
y cols.
MRI of Cardiomyopathy.
AJR 2008:191:1702-1710.
- O’Donnell DH,
Abbara S,
Chaithiraphan V.
y cols.
Cardiac MR Imaging of Nonischemic Cardiomyopathies: Imaging Protocols and Spectra of Appearances.
Radiology 2012,
262,
403-422.
- Perugini E,
Rapezzi C,
Piva T.y cols.
Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance.Heart 2006;92:343-349.
- Maceira AM,
Joshi J,
Prasad DK y cols.
Cardiovascular Magnetic Resonance in Cardiac Ayloidosis.
Circulation 2005;111:186-193.
- Syed IS,
Glockner JF,
Feng D,
y cols.
Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis [Internet].
Journal of the American College of Cardiology: Cardiovascular Imaging 2010 Feb;3(2):155-164.
- 10.
Anderson LJ,
Holden S,
Davis B y cols.
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.
Eur Heart J 2001;22:2171-2179.
- 11.
Barosi G,
Arbustini E,
Gavazzi A y cols.
Myocardial iron grading by endomyocardial biopsy.
A clínico-pathologic study on iron overloaded patients.
Eur J Hematol 1989;42:382-388.
- 12.
Desnick RJ,
Brady R,
Barranger J y Collins AJ.
Fabry disease,
an underrecognized multisystemic disorder: expert recommendations for diagnosis,
management,
and enzyme replacement therapy.
Ann Intern Med.
2003;138:338.
- Sheppard MN.
The heart in Fabry's disease.
Cardiovascular Pathology 20 (2011) 8–14
- Moon JCC,
Sachdev B,
Elkington AG y cols.
Gadolunium-enhanced cardiovascular magnetic resonance in Andeson-Fabry disease.
Eur Heart J 2003;24:2151-2155.
- Kloner RA,
Hale S,
Alker K y cols.
The effects of acute and chronic cocaine use on the heart.
Circulation (1992) 85:407–419.
- Frishman WH,
Del Vecchio A,
Sanal S et al (2003) Cardiovascular manifestations of substance abuse part 1: cocaine.
Heart Dis 5:187– 201.
- Restrepo CS, Rojas CA,
Martinez S,
y cols.
Cardiovascular complications of cocaine: Imaging findingsEmerg Radiol (2009) 16:11–19.
- Vogel-Claussen J,
Rochitte CE,
Wu KC,
y cols.
Delayed Enhancement MR Imaging: Utility in Myocardial Assessment Radiographics 2006;26:795-810
- Nield LE,
Silverman ED,
Taylor GP,
y cols.
Maternal Anti-Ro and Anti-La Antibody-Associated Endocardial Fibroelastosis.
Circulation 2002;105:843-848.
- Chen S,
Thompson MW,
Rose V.
Endocardial fibroelastosis: family studies with special reference to counseling.
J Pediatr.
Sep 1971;79(3):385-92.
- Ogbogu PU,
Rosing DR,
Horne MK 3rd.
Cardiovascular manifestations of hypereosinophilic syndromes.
Immunol Allergy Clin North Am 2007;27(3):457–475.
- Cummings,
KW,
Bhalla S,
Javidan-Nejad C.A Pattern-based Approach to Assessment of Delayed Enhancement in Nonischemic Cardiomyopathy at MR Imaging.
RadioGraphics 2009; 29:89–103.
- Vignaux O.
Cardiac sarcoidosis: spectrum of MRI features.
AJR 2005;184:249-254.
- Smedema P,
Snoep G,
Van Kroonenburgh MPG,
y cols.
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis.
J Am Coll Cardiol 2005;45(10):1683-1690.
- Uemura A ,
Morimoto S ,
Hiramitsu S ,
y cols.
Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies .
Am Heart J 1999 ; 138 ( 2 Pt 1 ): 299 – 302.
- Asghar O,
Al-Sunni,
A.,
Khavandi,
K.
y cols.
Diabetic cardiomyopathy.
Clinical science 2009 May;116(10):741-60
- Tarquini R.,
Lazzeri C,
Pala y cols.
The diabetic cardiomyopathy.
Acta Diabetol. 2011 Sep;48(3):173-81.
- Maya L. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis.
J Mol Cell Cardiol.
2010 March ; 48(3): 524–529
- Melacini P,
Vianello A,
Villanova C,
y cols.
Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy.
Neuromusc Disord 1996;6: 367-376.
- Child JS,
Perloff JK,
Bach PM y cols.
Cardiac involvement in Friedreich´s ataxia.
J Am Coll Cardiol 1986; 7: 1.370-1.378.
- El Menyar A A,
Bener A,
Al Suwaidi J.
Cardiovascular manifestations of myofibrillar myopathy.
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 2004 Dec;4(4):336-8.
- Hurd ER.
Extraarticular manifestations of rheumatoid arthritis.
Sem Arthritis Rheum 1979;8:151–76
- Lebowitz WB.
The heart in rheumatoid arthritis (rheumatoid disease): a clinical and pathological study of 62 cases.
Ann Intern Med 1963;58:102–23.
- Guedes C.,
Bianchi/FIor P.,
Cornier,
P.
y cols. Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum.
2001 Apr;45(2):129-35.
- Maksimović R.
Seferovic P.
M.,
Ristic,
A.D.
y cols.
Cardiac imaging in rheumatic diseases.
Rheumatology (Oxford,
England) 2006 Oct; 45 Suppl 4:iv26-31.
- Kobayashi Y.,
Giles J.,
Hirano.
M.
y cols.
Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study.
Arthritis research & therapy 2010 Jan;12(5):R171.
- Dziadzio M,
Giovagnoni A,
Pomponio G y cols.
Acute myocarditis associated with adenoviral infection in a patient with scleroderma.
Clin Rheumatol 2003;22:487–90.
- Appenzeller S,
Pineau CA,
Clarke AE.
CASE REPORT Acute lupus myocarditis : Clinical features and outcome.
Mayo Clinic Proceedings 2011;981-988.
- Saremi F,
Ashikyan O,
Saggar R,
Vu J y Nunez ME.
Utility of cardiac MRI for diagnosis and post-treatment follow-up of lupus myocarditis.
The international journal of cardiovascular imaging 2007 Jun;23(3):347-52.
- Roman MJ,
Salmon JE,
Sobel R y cols. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001;87:663–6.
- Apte M,
McGwin G,
Vilá LM,
y cols. Associated factors and impact of myocarditis in patients with SLE from LUMINA,
a multiethnic US cohort (LV). Rheumatology 2008 Mar;47(3):362-7.
- Appenzeller S,
Pineau CA,
Clarke AE.
CASE REPORT Acute lupus myocarditis : Clinical features and outcome.
Mayo Clinic Proceedings 2011;981-988.
- Doria A,
Petri M (2004) Cardiac involvement in systemic lupus erythematosus.
In: Doria A,
Pauletto P(eds) The heart in systemic autoimmune disease.
Elsevier,
Amsterdam,
pp 146–162.
- Tzelepis GE,
Kelekis,
N.,
Platiras C.
y cols.
Pattern and Distribution of Myocardial Fibrosis in Systemic Sclerosis A Delayed Enhanced Magnetic Resonance Imaging Study.
Arthritis & Rheumatism 2007;56(11):3827-3836.)
- Petri S,
Esko V.
Esa J.
y col.
A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy.
Nucl Med Commun. 2012 Jan;33(1):51-9.)
- Catalano,
O.,
Antonaci S,
Moro G.
y cols.
Contrast-enhanced cardiac magnetic resonance in a patient with chemotoxic cardiomyopathy.
JCardiovascMed (Hagerstown). 2007 Mar;8(3):214-5.
- Yeh ETH,
Tong AT,
Lenihan,
DJ.
y cols.
Cardiovascular complications of cancer therapy: diagnosis,
pathogenesis,
and management.
Circulation 2004 Jun;109(25):3122-31.
- Machann W,
Beer M,
Breunig M y cols.
Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease.
Int J Radiat Oncol Biol Phys 2011 Mar;79(4):1117-23